CBP-501 is under clinical development by CanBas and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 72% phase transition success rate (PTSR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback